Genetically Modified T Cells for Esophageal Cancer Therapy: A Promising Clinical Application

Esophageal cancer is an exceedingly aggressive and malignant cancer that imposes a substantial burden on patients and their families. It is usually treated with surgery, chemotherapy, radiotherapy, and molecular-targeted therapy. Immunotherapy is a novel treatment modality for esophageal cancer wher...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yu-Ge Zhu, Bu-Fan Xiao, Jing-Tao Zhang, Xin-Run Cui, Zhe-Ming Lu, Nan Wu
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	T cell receptor chimeric antigen receptor immunotherapy engineered T cells esophageal cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/8b6f5dbffe974ed58a174342600c2fad
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8b6f5dbffe974ed58a174342600c2fad
record_format	dspace
spelling	oai:doaj.org-article:8b6f5dbffe974ed58a174342600c2fad2021-11-09T06:10:21ZGenetically Modified T Cells for Esophageal Cancer Therapy: A Promising Clinical Application2234-943X10.3389/fonc.2021.763806https://doaj.org/article/8b6f5dbffe974ed58a174342600c2fad2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.763806/fullhttps://doaj.org/toc/2234-943XEsophageal cancer is an exceedingly aggressive and malignant cancer that imposes a substantial burden on patients and their families. It is usually treated with surgery, chemotherapy, radiotherapy, and molecular-targeted therapy. Immunotherapy is a novel treatment modality for esophageal cancer wherein genetically engineered adoptive cell therapy is utilized, which modifies immune cells to attack cancer cells. Using chimeric antigen receptor (CAR) or T cell receptor (TCR) modified T cells yielded demonstrably encouraging efficacy in patients. CAR-T cell therapy has shown robust clinical results for malignant hematological diseases, particularly in B cell-derived malignancies. Natural killer (NK) cells could serve as another reliable and safe CAR engineering platform, and CAR-NK cell therapy could be a more generalized approach for cancer immunotherapy because NK cells are histocompatibility-independent. TCR-T cells can detect a broad range of targeted antigens within subcellular compartments and hold great potential for use in cancer therapy. Numerous studies have been conducted to evaluate the efficacy and feasibility of CAR and TCR based adoptive cell therapies (ACT). A comprehensive understanding of genetically-modified T cell technologies can facilitate the clinical translation of these adoptive cell-based immunotherapies. Here, we systematically review the state-of-the-art knowledge on genetically-modified T-cell therapy and provide a summary of preclinical and clinical trials of CAR and TCR-transgenic ACT.Yu-Ge ZhuBu-Fan XiaoJing-Tao ZhangXin-Run CuiZhe-Ming LuNan WuFrontiers Media S.A.articleT cell receptorchimeric antigen receptorimmunotherapyengineered T cellsesophageal cancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	T cell receptor chimeric antigen receptor immunotherapy engineered T cells esophageal cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	T cell receptor chimeric antigen receptor immunotherapy engineered T cells esophageal cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Yu-Ge Zhu Bu-Fan Xiao Jing-Tao Zhang Xin-Run Cui Zhe-Ming Lu Nan Wu Genetically Modified T Cells for Esophageal Cancer Therapy: A Promising Clinical Application
description	Esophageal cancer is an exceedingly aggressive and malignant cancer that imposes a substantial burden on patients and their families. It is usually treated with surgery, chemotherapy, radiotherapy, and molecular-targeted therapy. Immunotherapy is a novel treatment modality for esophageal cancer wherein genetically engineered adoptive cell therapy is utilized, which modifies immune cells to attack cancer cells. Using chimeric antigen receptor (CAR) or T cell receptor (TCR) modified T cells yielded demonstrably encouraging efficacy in patients. CAR-T cell therapy has shown robust clinical results for malignant hematological diseases, particularly in B cell-derived malignancies. Natural killer (NK) cells could serve as another reliable and safe CAR engineering platform, and CAR-NK cell therapy could be a more generalized approach for cancer immunotherapy because NK cells are histocompatibility-independent. TCR-T cells can detect a broad range of targeted antigens within subcellular compartments and hold great potential for use in cancer therapy. Numerous studies have been conducted to evaluate the efficacy and feasibility of CAR and TCR based adoptive cell therapies (ACT). A comprehensive understanding of genetically-modified T cell technologies can facilitate the clinical translation of these adoptive cell-based immunotherapies. Here, we systematically review the state-of-the-art knowledge on genetically-modified T-cell therapy and provide a summary of preclinical and clinical trials of CAR and TCR-transgenic ACT.
format	article
author	Yu-Ge Zhu Bu-Fan Xiao Jing-Tao Zhang Xin-Run Cui Zhe-Ming Lu Nan Wu
author_facet	Yu-Ge Zhu Bu-Fan Xiao Jing-Tao Zhang Xin-Run Cui Zhe-Ming Lu Nan Wu
author_sort	Yu-Ge Zhu
title	Genetically Modified T Cells for Esophageal Cancer Therapy: A Promising Clinical Application
title_short	Genetically Modified T Cells for Esophageal Cancer Therapy: A Promising Clinical Application
title_full	Genetically Modified T Cells for Esophageal Cancer Therapy: A Promising Clinical Application
title_fullStr	Genetically Modified T Cells for Esophageal Cancer Therapy: A Promising Clinical Application
title_full_unstemmed	Genetically Modified T Cells for Esophageal Cancer Therapy: A Promising Clinical Application
title_sort	genetically modified t cells for esophageal cancer therapy: a promising clinical application
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/8b6f5dbffe974ed58a174342600c2fad
work_keys_str_mv	AT yugezhu geneticallymodifiedtcellsforesophagealcancertherapyapromisingclinicalapplication AT bufanxiao geneticallymodifiedtcellsforesophagealcancertherapyapromisingclinicalapplication AT jingtaozhang geneticallymodifiedtcellsforesophagealcancertherapyapromisingclinicalapplication AT xinruncui geneticallymodifiedtcellsforesophagealcancertherapyapromisingclinicalapplication AT zheminglu geneticallymodifiedtcellsforesophagealcancertherapyapromisingclinicalapplication AT nanwu geneticallymodifiedtcellsforesophagealcancertherapyapromisingclinicalapplication
_version_	1718441313021460480

Genetically Modified T Cells for Esophageal Cancer Therapy: A Promising Clinical Application

Ejemplares similares